Resources

85 Resources for

john maas

  • Subscribe to this listing via:
  • RSS
  • Email
BNET Author Biography
John Maas is a former BNET intern.
more about John Maas »

BNET Resources

Pharma Roundup: Cephalon Hikes Provigil Prices, Icahn Eyes Amylin, and More
Cephalon hopes Provigil price hikes now will keep its customers later. Icahn wants Amylin, perhaps. Johnson & Johnson pays for Duragesic death. Anti-depressants may be equivalent. by John Maas
Tags: Cephalon Inc., Icahn, John Maas, Johnson & Johnson, Provigil, Patches, Security
Blog posts 2008-11-18
Pharma Roundup: Roche and Novartis CEO Predictions, ImClone Cuts, and More
Roche CEO sees industry trouble, Novartis CEO wants to stay, ImClone cuts reps, Allergan eyelash-lengthener gets thumbs up. by John Maas
Tags: Roche Holding AG, Forbes, Novartis AG, Allergan Inc., CEO, Federal Government, Strategy, Sales Strategy, Mergers & Acquisitions, Sales Force Management, Government, Management, Sales, Investment, Finance, John Maas
Blog posts 2008-12-08
Pharma Roundup: Merck Eyes Generics, Pfizer Delays Layoffs, and More
Merck launches generics business, Pfizer delays layoffs, Europe can continue to repackage drugs. by John Maas
Tags: Layoff, Pfizer Inc., Generic, Merck & Co. Inc., Repackaging, Biotechnology, Workforce Management, Human Resources, John Maas
Blog posts 2008-12-09
Pharma Roundup: Elan's Martin, Biotech's Worst CEO; Executive Shake-Up at Sanofi; and More
Elan's Kelly Martin as biotech's worst CEO? Also, Sanofi's executive VP departs, biotechs seek federal aid, and Congress may debate potential DTC ban. by John Maas
Tags: Executive Vice President, TheStreet.com Inc., Elan, Biotechnology, Taxes, Financial Planning, Finance, John Maas
Blog posts 2008-12-10
Pharma Roundup: Infinity and AstraZeneca Split, Schering & Merck's PR Blunder, and More
A fond farewell between Infinity and AstraZeneca, a dubious PR honor for S-P and Merck over Vytorin, Lilly's ImClone-related costs mount, generics cost less. by John Maas
Tags: AstraZeneca Plc., Merck & Co. Inc., MedImmune Inc., AZ, Public Relations, Business Structures, Marketing, Corporate Communications, Finance, John Maas
Blog posts 2008-12-11
Pharma Roundup: Schering-Plough's $500,000 Bonus, Bristol and Exelixis, and More
Cash-strapped Schering-Plough gives out $500,000 bonus; Bristol-Myers Squibb buys chunk of Exelixis pipeline; Pfizer and Elan cut jobs. by John Maas
Tags: Job, Pfizer Inc., Bonus, Schering-Plough Corp., Recruitment & Selection, Human Resources, Workforce Management, John Maas
Blog posts 2008-12-12
Pharma Roundup: Bayer Boosts R&D, AstraZeneca Outsources, Titan Execs Leave, and More
Bayer boosts spending on research and development, AstraZeneca contracts with India's Infosys for IT support, Titan loses two execs, biotech acquisitions increase. by John Maas
Tags: AstraZeneca Plc., Bayer AG, R&D, Outsource, Research & Development, Biotechnology, Supply Chain Management (SCM), Business Operations, Enterprise Software, Software, John Maas
Blog posts 2008-12-15
Pharma Roundup: Feds Sue Ovation, Bristol Cuts Jobs, and More
Ovation faces federal lawsuit for price gouging, Bristol lays off 10 percent, Pfizer freezes dividend, Jazz eliminates 71 positions. by John Maas
Tags: Job, Ovation, Pharmaceutical Company, Feds, Government, Recruitment & Selection, Human Resources, Workforce Management, John Maas
Blog posts 2008-12-16
Pharma Roundup: New Jobs at Charles River, Texas Sues J&J Subsidiary, and More
Charles River comes to Charleston, brings jobs; Texas sues J&J unit Janssen; court victory for PTC Therapeutics in landmark clinical trials case. by John Maas
Tags: Job, Public Health, Johnson & Johnson, Healthcare, John Maas
Blog posts 2008-12-17
Pharma Roundup: Novo Nordisk's Growth Strategy, Disclosure at Cleveland and Penn, and More
Novo Nordisk is looking for growth in the developed world. The Cleveland Clinic and the hospital at Penn announced disclosure policies this week. The UK biotech industry is worried. by John Maas
Tags: Strategy, Forbes, Pharmaceutical Company, John Maas
Blog posts 2008-12-05
Pharma Roundup: Sanofi Axes Reps, Glaxo Fights Patent Office, and More
Sanofi-Aventis cuts 650 sales reps, Glaxo heads to court, FDA deals Roche a setback, Deerfield may purchase all of Nitromed. by John Maas
Tags: Roche Holding AG, Pharmaceutical Company, U.S. Patent And Trademark Office, GSK, Sales Strategy, IPO, Research & Development, Federal Government, Sales Force Management, Sales, Financial Services, Business Operations, Government, John Maas
Blog posts 2008-12-04
Pharma Roundup: Goldman Sachs Funds R&D, Novartis and Evotec, and More
Goldman Sachs funds new pharma business model. Novartis and Evotec sign $28 million pact. Genentech claims in-house morale remains high, even with looming Roche buyout. by John Maas
Tags: Business Operations, Genentech Inc., Goldman Sachs Group Inc., John Maas, Management, Novartis AG, R&D, Research & Development, Strategy
Blog posts 2008-12-03
Pharma Roundup: Lawsuit for Roche, Teva Troubles for AstraZeneca, and More
Roche must pay in lawsuit, Teva aiming for AstraZeneca's customers, AstraZeneca's new U.S. president, and Novartis in Cambridge. by John Maas
Tags: AstraZeneca Plc., Lawsuit, Roche Holding AG, John Maas, Teva, AZ, Federal Government, Government
Blog posts 2008-11-19
Pharma Roundup: Novartis Pipeline, AstraZeneca Layoffs, and More
Novartis pipeline, AstraZeneca layoffs, Merck's self-proclaimed goodness, lessons for pharma from Detroit. by John Maas
Tags: AstraZeneca Plc., Layoff, Blog, Novartis AG, Pharmaceutical Company, Blogging, Internet, John Maas
Blog posts 2008-11-20
Pharma Roundup: ImClone a Done Deal, FDA Approvals Up, and More
ImClone leaving the headlines at last, perhaps; FDA beats last year's approval rate, despite a string of delays; a good biotech merger for a bad economy. by John Maas
Tags: FDA, Compound, Archemix, Federal Government, Government, John Maas
Blog posts 2008-11-21
Pharma Roundup: Schering-Plough's Pipeline, Pfizer's Pipeline, and More
Schering-Plough claims robust pipeline; Pfizer's pipeline grows steadily; King finally owns Alpharma; Johnson & Johnson owns Omrix. by John Maas
Tags: Pfizer Inc., Schering-Plough Corp., Pipeline, Federal Government, Blogging, Government, Internet, John Maas
Blog posts 2008-11-24
Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More
AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas
Tags: AstraZeneca Plc., Pfizer Inc., M&A, Pharmaceutical Company, Indonesia, Mergers & Acquisitions, Outsourcing, Investment, Finance, It Operations, Business Operations, Outsourcing & Subcontracting, John Maas
Blog posts 2008-11-25
Pharma Roundup: Roche Buys Memory, Biotech in NC, and More
Roche purchases Memory Pharmaceuticals, North Carolina biotech industry seeks government help, the 5 biggest layoff announcements of 2008. by John Maas
Tags: Roche Holding AG, Memory, Pharmaceutical Company, Network Computer, Biotechnology, John Maas
Blog posts 2008-11-26
Pharma Roundup: Teva and Lilly, Roche and Genentech, and More
Lilly may be Teva's next unwilling partner in the patent dance. The Roche-Genentech deal will need an enormous loan. The EU declares "war on pharma." by John Maas
Tags: Roche Holding AG, Pharmaceutical Company, Genentech Inc., Teva, John Maas
Blog posts 2008-12-01
Pharma Roundup: Roche's DTC Regrets, Novartis and Mylan, and More
Roche CEO: DTC ads industry's "worst decision." Novartis and Mylan reach patent deal. Trouble in Biotech-land. AmerisourceBergen and its thrifty CEO. by John Maas
Tags: Roche Holding AG, Breast Cancer, Novartis AG, Pharmaceutical Company, Biotechnology, John Maas
Blog posts 2008-12-02
advertisement
advertisement